ECSP21015267A - Compuestos de 2,6-diaminopiridina - Google Patents

Compuestos de 2,6-diaminopiridina

Info

Publication number
ECSP21015267A
ECSP21015267A ECSENADI202115267A ECDI202115267A ECSP21015267A EC SP21015267 A ECSP21015267 A EC SP21015267A EC SENADI202115267 A ECSENADI202115267 A EC SENADI202115267A EC DI202115267 A ECDI202115267 A EC DI202115267A EC SP21015267 A ECSP21015267 A EC SP21015267A
Authority
EC
Ecuador
Prior art keywords
formula
compounds
diaminopyridine compounds
diaminopyridine
compound
Prior art date
Application number
ECSENADI202115267A
Other languages
English (en)
Inventor
Timothy Barrett Durham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21015267A publication Critical patent/ECSP21015267A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I (VER ANEXO) o una sal farmacéuticamente aceptable de este, y el uso de los compuestos de Fórmula I para el tratamiento de afecciones metabólicas, tales como la diabetes mellitus tipo 2, la insuficiencia cardíaca, la enfermedad renal diabética y la esteatohepatitis no alcohólica.
ECSENADI202115267A 2018-09-04 2021-03-03 Compuestos de 2,6-diaminopiridina ECSP21015267A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726520P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
ECSP21015267A true ECSP21015267A (es) 2021-04-29

Family

ID=67982138

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202115267A ECSP21015267A (es) 2018-09-04 2021-03-03 Compuestos de 2,6-diaminopiridina

Country Status (28)

Country Link
US (1) US10781212B2 (es)
EP (1) EP3846809B1 (es)
JP (1) JP6813720B1 (es)
KR (1) KR102365535B1 (es)
CN (1) CN112601525B (es)
AR (1) AR117640A1 (es)
AU (1) AU2019334877B2 (es)
BR (1) BR112021001881A2 (es)
CA (1) CA3111725C (es)
CL (1) CL2021000528A1 (es)
CO (1) CO2021002768A2 (es)
CR (1) CR20210085A (es)
DO (1) DOP2021000027A (es)
EA (1) EA202190302A1 (es)
EC (1) ECSP21015267A (es)
ES (1) ES2971802T3 (es)
IL (1) IL280598B2 (es)
JO (1) JOP20210039B1 (es)
MA (1) MA53547A (es)
MX (1) MX2021002472A (es)
MY (1) MY200531A (es)
PE (1) PE20211595A1 (es)
PH (1) PH12021550449A1 (es)
SG (1) SG11202101687TA (es)
TW (1) TWI714231B (es)
UA (1) UA124917C2 (es)
WO (1) WO2020051058A1 (es)
ZA (1) ZA202100700B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161621B2 (en) 2018-07-16 2024-12-10 The Regents Of The University Of Colorado Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease
TWI750685B (zh) * 2019-06-17 2021-12-21 美商美國禮來大藥廠 二取代吡唑化合物
US12534477B2 (en) 2019-12-24 2026-01-27 Hangzhou Zhongmeihuadong Pharmaceutical Co. , Ltd. Compound having KHK inhibitory effect
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
EP4313967B1 (en) 2021-03-29 2025-11-12 Gilead Sciences, Inc. Khk inhibitors
MX2024009161A (es) * 2022-01-26 2024-08-06 Lilly Co Eli Compuestos de pirrolidina.
US20250145619A1 (en) * 2022-02-09 2025-05-08 Youngene Therapeutics Co., Ltd Khk inhibitor, preparation method therefor and use thereof
WO2024121183A1 (en) * 2022-12-08 2024-06-13 Boehringer Ingelheim International Gmbh New cyanopyridine khk inhibitor compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663511C (en) * 2006-09-20 2012-12-04 Eli Lilly And Company Thiazole pyrazolopyrimidines as crf1 receptor antagonists
AR099937A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
LT3154959T (lt) * 2014-05-15 2019-09-25 Array Biopharma, Inc. 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Also Published As

Publication number Publication date
KR102365535B1 (ko) 2022-02-23
CN112601525A (zh) 2021-04-02
PE20211595A1 (es) 2021-08-18
EP3846809B1 (en) 2023-12-13
CA3111725A1 (en) 2020-03-12
WO2020051058A1 (en) 2020-03-12
NZ774406A (en) 2024-09-27
JP2021506949A (ja) 2021-02-22
ES2971802T3 (es) 2024-06-07
US10781212B2 (en) 2020-09-22
MA53547A (fr) 2022-04-27
SG11202101687TA (en) 2021-03-30
TWI714231B (zh) 2020-12-21
PH12021550449A1 (en) 2021-09-27
JOP20210039B1 (ar) 2024-04-18
CR20210085A (es) 2021-04-29
DOP2021000027A (es) 2021-03-15
CN112601525B (zh) 2023-11-10
AR117640A1 (es) 2021-08-18
CA3111725C (en) 2022-12-13
AU2019334877B2 (en) 2022-07-28
KR20210034082A (ko) 2021-03-29
US20200071331A1 (en) 2020-03-05
UA124917C2 (uk) 2021-12-08
MY200531A (en) 2023-12-31
ZA202100700B (en) 2022-09-28
CO2021002768A2 (es) 2021-05-20
CL2021000528A1 (es) 2021-07-30
EA202190302A1 (ru) 2021-06-10
TW202026289A (zh) 2020-07-16
MX2021002472A (es) 2021-04-29
EP3846809A1 (en) 2021-07-14
JOP20210039A1 (ar) 2021-03-04
JP6813720B1 (ja) 2021-01-13
IL280598B1 (en) 2023-10-01
IL280598B2 (en) 2024-02-01
IL280598A (en) 2021-03-25
AU2019334877A1 (en) 2021-03-11
BR112021001881A2 (pt) 2021-04-27

Similar Documents

Publication Publication Date Title
ECSP21015267A (es) Compuestos de 2,6-diaminopiridina
CL2021003342A1 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
CL2022003395A1 (es) Antagonistas del receptor de lpa y usos de los mismos
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
EA201990518A1 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MX382748B (es) Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
NI201200005A (es) Terapia de combinación para el tratamiento de la diabetes
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
MX389091B (es) Tratamiento de pacientes con diabetes mellitus de tipo 2.
MX2019010108A (es) Derivados de azetidina.
CL2025001515A1 (es) Uso de finerenona para tratar la enfermedad renal crónica en la diabetes mellitus tipo i.
AR100420A1 (es) Derivados bicíclicos y composición farmacéutica que los incluye
AR109895A1 (es) Compuestos cíclicos de péptido tirosina tirosina como moduladores de neuropéptido y receptores
AR119173A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
EA202192957A1 (ru) Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы
CL2018002677A1 (es) Composición farmacéutica que comprende a) metformina, b) rosiglitazona o pioglitazona, c) sitagliptina, linagliptina o vildagliptina, y excipientes; y su uso para el tratamiento del desarrollo de ehna, sindrome de insulino-resistencia y la diabetes mellitus tipo 2, sop.
AR115865A2 (es) Compuestos terapéuticos
AR105924A1 (es) Compuestos terapéuticos y síntesis